NR1H4 and Hepatic fibrosis: Since FXR agonists convey beneficial effects in preclinical models of liver fibrosis and portal hypertension [60], it is highly anticipated that TGR5/FXR double-KO mice will also develop LSEC and HSC dysfunction and portal hypertension.